Uncategorized
Fueled by M&A and partnerships, biotech is poised for continued growth: EY
Biotech’s effervescent activity has allowed it to overcome headwinds and sustain momentum into 2026, as the volume and value of licensing and M&A deals continues to increase. New IPOs and the recovery of venture capital funding are helping, as well.